aTyr Pharma Inc. (LIFE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.95+0.10 (+3.51%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close2.85
Bid2.80 x 1600
Ask3.40 x 100
Day's Range2.80 - 2.97
52wk Range2.48 - 13.26
1y Target EstN/A
Market Cap69.97M
P/E Ratio (ttm)-1.18
Avg Vol (3m)197,316
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Investopedia9 hours ago

    aTyr Pharma Receives Fast Track Designation (LIFE)

    Companies receiving Fast Track designation from the FDA can signal positive things for companies like aTyr Pharma and its orphan drugs.

  • 24/7 Wall St.2 days ago

    aTyr Receives FDA Fast Track Designation

    aTyr Pharma watched its shares climb early on Monday after the company announced that its product candidate Resolaris was granted Fast Track designation by the FDA.

  • PR Newswire3 days ago

    aTyr Pharma Receives FDA Fast Track Designation for Resolaris™ to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)

    SAN DIEGO, Oct. 24, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that its product candidate Resolaris™ was granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of facioscapulohumeral muscular dystrophy (FSHD), making it the first known therapeutic candidate for the treatment of FSHD to receive the designation.  Resolaris, a designated Orphan Drug in FSHD, is currently being studied in a Phase 1b/2 clinical program. "This Fast Track designation, which is granted to drug candidates addressing serious conditions and that demonstrate the potential to address unmet medical needs, represents another step forward for our rare muscle disease franchise," said John Mendlein, PhD, CEO of aTyr Pharma.